XOMA ROYALTY (XOMA)
(Delayed Data from NSDQ)
$27.00 USD
+0.03 (0.11%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $26.95 -0.05 (-0.19%) 6:18 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
XOMA 27.00 +0.03(0.11%)
Will XOMA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for XOMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XOMA
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?
Certara, Inc. (CERT) Q1 Earnings Meet Estimates
XOMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
Xoma (XOMA) Moves 7.7% Higher: Will This Strength Last?
Other News for XOMA
XOMA Declares Quarterly Preferred Stock Dividends
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
Xoma receives $8.1M milestone related to Day One's sale of PRV
3 Crazy Good Stocks to Buy With $500 Right Now
ImmunityBio, LadRx end licensing deal for cancer drug